These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6375562)

  • 1. Pharmacokinetics of ceftazidime in normal and uremic subjects.
    Leroy A; Leguy F; Borsa F; Spencer GR; Fillastre JP; Humbert G
    Antimicrob Agents Chemother; 1984 May; 25(5):638-42. PubMed ID: 6375562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
    Welage LS; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP
    Antimicrob Agents Chemother; 1981 Jun; 19(6):965-71. PubMed ID: 6455967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of decreased renal function on the pharmacokinetics of ceftazidime.
    Ackerman BH; Ross J; Tofte RW; Rotschafer JC
    Antimicrob Agents Chemother; 1984 Jun; 25(6):785-6. PubMed ID: 6378087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.
    Kashuba AD; Ballow CH; Forrest A
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1860-5. PubMed ID: 8843294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefsulodin pharmacokinetics in patients with various degrees of renal function.
    Matzke GR; Keane WF
    Antimicrob Agents Chemother; 1983 Mar; 23(3):369-73. PubMed ID: 6847169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of ceftazidime in ascitic fluid.
    Benoni G; Arosio E; Raimondi MG; Apolloni E; Passarella E; Lechi A; Velo GP
    Antimicrob Agents Chemother; 1984 Jun; 25(6):760-3. PubMed ID: 6378086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofloxacin pharmacokinetics in renal failure.
    Fillastre JP; Leroy A; Humbert G
    Antimicrob Agents Chemother; 1987 Feb; 31(2):156-60. PubMed ID: 3471179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of habekacin in patients with renal insufficiency.
    Fillastre JP; Leroy A; Humbert G; Moulin B; Bernadet P; Josse S
    Antimicrob Agents Chemother; 1987 Apr; 31(4):575-7. PubMed ID: 3606062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal function.
    Nielsen OS; Toothaker RD; Bundtzen RW; Craig WA; Welling PG; Madsen PO
    Infection; 1980; 8 Suppl 3():S 305-9. PubMed ID: 6250981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.
    Paulfeuerborn W; Müller HJ; Borner K; Koeppe P; Lode H
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1835-41. PubMed ID: 8239592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefonicid in uraemic patients.
    Fillastre JP; Fourtillan JB; Leroy A; Ramis N; Lefevre MA; Reumont G; Humbert G
    J Antimicrob Chemother; 1986 Aug; 18(2):203-11. PubMed ID: 3759731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid.
    Walstad RA; Hellum KB; Blika S; Dale LG; Fredriksen T; Myhre KI; Spencer GR
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():275-82. PubMed ID: 6352632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.
    Merdjan H; Tarral A; Das S; Li J
    J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime disposition in acute and stable cystic fibrosis.
    Leeder JS; Spino M; Isles AF; Tesoro AM; Gold R; MacLeod SM
    Clin Pharmacol Ther; 1984 Sep; 36(3):355-62. PubMed ID: 6432400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.